<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/7B771191-25B9-47D3-B30F-CAA1FB33C68D"><gtr:id>7B771191-25B9-47D3-B30F-CAA1FB33C68D</gtr:id><gtr:name>Psioxus Therapeutics Limited</gtr:name><gtr:address><gtr:line1>154B BROOK DRIVE , MILTON PARK</gtr:line1><gtr:city>ABINGDON</gtr:city><gtr:postCode>OX14 4SD</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7B771191-25B9-47D3-B30F-CAA1FB33C68D" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>7B771191-25B9-47D3-B30F-CAA1FB33C68D</gtr:id><gtr:name>Psioxus Therapeutics Limited</gtr:name><gtr:address><gtr:line1>154B BROOK DRIVE , MILTON PARK</gtr:line1><gtr:city>ABINGDON</gtr:city><gtr:postCode>OX14 4SD</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>1727687.0</gtr:offerGrant><gtr:projectCost>3455373.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B28AB436-EC5D-4F4E-8E32-8E2AE8D7AA4C"><gtr:id>B28AB436-EC5D-4F4E-8E32-8E2AE8D7AA4C</gtr:id><gtr:firstName>carole</gtr:firstName><gtr:surname>ireson</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=101374"><gtr:id>7C41BBA5-6F55-478D-898F-325C39A08FA1</gtr:id><gtr:title>OCTAVE - Ovarian Cancer Trial with an Enhanced Group B Oncolytic Adenovirus</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>101374</gtr:grantReference><gtr:abstractText>ColoAd1 is a chimeric adenovirus serotype 3/11p, with a number of key characteristics that may make it a suitable oncolytic agent for the potential treatment of metastatic carcinomas. This is a phase I/IIa study designed to determine the safety, toxicity and tolerability of ColoAd1 and the clinical benefit and potential efficacy of ColoAd1 as a single agent and in combination with chemotherapy in women with recurrent platinum resistant ovarian cancer when administered intraperitoneally. Safety evaluations will be will be assessed using NCI CTCAE v4 and efficacy evaluations will be assessed using CT and [18F]-FDG PET/CT scans. A number of pharmacogenomics and biomarker assessments will also be performed.</gtr:abstractText><gtr:fund><gtr:end>2016-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1727687</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">101374</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>